The Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Program

The goal of the NIA-funded TREAT-AD consortium ( is to translate molecular signatures of late-onset Alzheimer’s disease into new treatments. As part of this program, the Emory/Sage/SGC TREAT-AD Center was initiated in 2019 to diversify the portfolio of drug targets in Alzheimer’s disease (AD), in which JAX CADR member Greg Carter is a Principal Investigator and the Head of Bioinformatics. The computational challenge of this project begins with mining human and mouse study data to identify key molecular factors that drive disease origin and progression. We then integrate multiple diverse data streams to formulate testable hypotheses for therapeutic interventions. Our collaborative, multi-institutional work is then combined with center components focused on assay development, structural biology, medicinal chemistry, and the neuroscience of disease to generate data and resources to develop precision therapies for late-onset AD. Our partners in this project include Emory University, Sage Bionetworks, the Structural Genoimcs Consortium at the Universities of Toronto and Oxford, the University of North Carolina and Stanford University. The TREAT-AD center is in turn a part of a major open science initiative to understand and treat Alzheimer’s disease that includes the AMP-AD, ADNI, ADSP, Resilience-AD, MOVE-AD, and MODEL-AD research consortia.